KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.

Rakesh Popat, Meral Beksac, Meletios A Dimopoulos, Moshe E Gatt, Francesca Gay, Jae-Cheol Jo, Prashant Kapoor, Eirini Katodritou, K Martin Kortüm, Silvia Ling, Chandramouli Nagarajan, Kenshi Suzuki, Lugui Qiu, Maika Onishi, Grace Ku, Monique Dail, Nabanita Mukherjee, Jeremy A Ross, Mohamed Ali Badawi, Mary Jean Fusco, Edyta Dobkowska, Emma Arriola, Orlando F Bueno, Nizar J Bahlis, Shinsuke Iida, Philippe Moreau, Jason Valent, María-Victoria Mateos

J Clin Oncol 44(3) 164-175

PMID41370738
PMCIDPMC12794717
DOI10.1200/JCO-25-00924
发表日期2025-12-10
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: Venetoclax, an oral BCL-2 inhibitor, has efficacy in t(11;14)-positive relapsed/refractory multiple myeloma (RRMM), which is enhanced by dexamethasone, which promotes BCL-2 dependency. METHODS: The randomized, open-label, phase III CANOVA study (ClinicalTrials.gov identifier: NCT03539744) enrolled adults with t(11;14)-positive RRMM who had received ≥2 previous lines of therapy. Patients were randomly assigned (1:1) to venetoclax-dexamethasone or pomalidomide-dexamethasone until progression or intolerable toxicity. The primary end point was independent review committee assessed-progression-free survival (PFS) in the intention-to-treat population analyzed by stratified log-rank test (two-sided type I error rate, α = .05), with hazard ratio (HR) and 95% CI estimated by stratified Cox proportional hazard model. Secondary end points included response rates, overall survival (OS), minimal residual disease (MRD) negativity rate (<10-5), and safety. RESULTS: Overall, 263 patients were randomly assigned (venetoclax-dexamethasone, n = 133; pomalidomide-dexamethasone, n = 130). Median PFS was 9.9 months (95% CI, 6.9 to 12.6) with venetoclax-dexamethasone versus 5.8 months (95% CI, 3.8 to 9.2) with pomalidomide-dexamethasone (HR, 0.823 [95% CI, 0.596 to 1.136]; P = .24). Overall response and very good partial response or better rates were 62% and 39%, respectively, with venetoclax-dexamethasone versus 35% and 14% with pomalidomide-dexamethasone. MRD negativity rate was 8% with venetoclax-dexamethasone and 0% with pomalidomide-dexamethasone. Median OS was 32.4 months (95% CI, 26.4 to 40.7) with venetoclax-dexamethasone and 26.9 months (95% CI, 20.4 to 38.9) with pomalidomide-dexamethasone (HR, 0.856 [95% CI, 0.612 to 1.197]). Grade ≥3 treatment-emergent adverse event rates were 67% with venetoclax-dexamethasone versus 83% with pomalidomide-dexamethasone. There were 16 (12%) treatment-emergent deaths with venetoclax-dexamethasone versus 8 (6%) with pomalidomide-dexamethasone. CONCLUSION: The primary end point of PFS was not met. PFS and OS were numerically longer with venetoclax-dexamethasone versus pomalidomide-dexamethasone in t(11;14)-positive RRMM. Consistent with previous studies, infections were associated with venetoclax-dexamethasone; no new safety signals were observed.

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure3 个面板

FIG 2.

FIG 2. (A) PFS as assessed by IRC, (B) EFS, and (C) TTNT in the intention-to-treat population. a HR and corresponding 95% CI were determined by using stratified Cox proportional hazard model. b P value was determined by using stratified log-rank test. EFS, event-free survival; HR, hazard ratio; IRC, independent review committee; PFS, progression-free survival; PomDex, pomalidomide and dexamethasone; TTNT, time to next treatment; VenDex, venetoclax and dexamethasone.

A

PFS

FIG 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme jump曲线 2:extreme upward reversal
查看结果
B

EFS

FIG 2. · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:short span曲线 2:extreme jump曲线 2:extreme upward reversal
查看结果
C

TTNT

FIG 2. · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure1 个面板

FIG 3.

FIG 3. (A) Response rates, (B) MRD negativity rates, and (C) OS in the intention-to-treat population. a HR and corresponding 95% CI were determined by using stratified Cox proportional hazard model. b Includes two additional patients who had not yet been randomly assigned at the time of the primary analysis data cutoff date. CR, complete response; HR, hazard ratio; MRD, minimal residual disease; NE, not evaluable; ORR, overall response rate; OS, overall survival; PD, progressive disease; PomDex, pomalidomide and dexamethasone; PR, partial response; sCR, stringent complete response; VenDex, venetoclax and dexamethasone; VGPR, very good PR.

C

OS

FIG 3. · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. CONSORT diagram. a The most common reasons patients did not meet enrollment eligibility after screening were lack of t(11;14) after central laboratory analysis, other (eg, CNS disease, death, traumatic accident), and laboratory values that did not meet eligibility criteria. ITT, intention-to-treat; PD, progressive disease; PomDex, pomalidomide and dexamethasone; VenDex, venetoclax and dexamethasone.
非 KM Figure